HSBC Downgrades Leading Drugmaker Stock to 'Hold' Citing Tough Path Ahead

HSBC analysts have downgraded a leading drugmaker's stock to 'hold,' stating that they no longer find the risk-reward balance attractive and forecast a 'tough path ahead' for the company.

14 Jul, 11:52 — 14 Jul, 11:52

Post Share

Sources

Showing 1 of 1 sources

cnbcMostly Factual47d ago

HSBC loses conviction in leading drugmaker, forecasts 'tough path' ahead

The bank's analysts wrote in a note on Monday that they have downgraded the stock to 'hold', as the team "no longer finds the risk-reward balance attractive."

Read full article →

HSBC Downgrades Leading Drugmaker Stock to 'Hold' Citing Tough Path Ahead

Sources

HSBC loses conviction in leading drugmaker, forecasts 'tough path' ahead

Related Stories

Seven Dead as Passenger Ferry Sinks Off Northern Cyprus

Deadly Flash Floods Strike Nepal-China Border Region

Inmate Escapes Duisburg Prison by Climbing Over Roof

Montenegrin Man Arrested After Admitting to Fatal Car Crash Involving Infant